Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biotech company with its forte in therapeutic treatments in the department of oncology especially of breast cancer, has been on a roller coaster ride recently. Based in Seattle the company gained much of the investors’ attention in the last year especially as it shifted much of its focus to treating Covid-19 as well, is a hot pick of the initial “meme stock” wave.
However, once the high wore off, the stock started falling from last June. The stock is currently at a low of over $2.90 as compared to its high of $9.80 per share. The company does have the potential of coming back strongly with its promising drugs like Endoxifen, AT-H201, etc. However, it does not seem enough to gain the confidence of investors- indicating continuing fall in the share prices.
The last year’s high was a one-time deal – with the stock being included in indices as well as high short interest. This time around, however, the risks of the company’s promising candidates dying down is outweighing the potential gains. This will remain the case for the future as well unless the company can turn the tables with its drugs.For now, it is worth waiting for the shares to pick up rather than considering it a high-risk high-return stock.